Biotech Updates

Initial Trials of Nasal Spray Vaccine for COVID-19 and Flu Show Positive Results

July 21, 2021

A genetically engineered nasal spray vaccine for COVID-19 and flu called Delta-19 showed positive preclinical data. Delta-19, being developed by Vivaldi Biosciences, is expected to provide superior protection to both viral respiratory diseases.

Studies using the ferret model resulted in 100% immunized animals that generated high amounts of antibodies against the COVID-19 virus, SARS-CoV-2. Furthermore, the immunized ferrets exhibited negligible amounts of SARS-CoV-2 in their noses and mouths, while high levels of the virus were observed in the control ferrets. Based on the initial results, Delta-19 has the potential to help achieve sterilizing immunity by preventing the replication of SARS-CoV-2 in the upper respiratory tract and transmission to other individuals.

Read the news release from Vivaldi Biosciences.

You might also like: